SCHEMBL6010797

SCHEMBL6010797

CC(C)(C)OC(=O)N1CCN(C[C@H](O)Cn2cc([N+](=O)[O-])nc2Cl)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.44
ALDH1A1 P00352 2/20 0.42
MAPT P10636 2/20 0.42
LMNA P02545 2/20 0.42
VEGFA P15692 1/20 0.39
EGLN1 Q9GZT9 1/20 0.39
HTT P42858 2/20 0.39
POLB P06746 1/20 0.39
ATM Q13315 1/20 0.39
KCNH2 Q12809 1/20 0.38
CTSS P25774 1/20 0.36
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
STS P08842 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM1 P11229 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5535042 1.00 ABCB1 (0.44) ABCB1ALDH1A1MAPTLMNAVEGFA
SCHEMBL6010674 1.00 ABCB1 (0.44) ABCB1ALDH1A1MAPTLMNAVEGFA
SCHEMBL5542335 0.84 LMNA (0.40) ALDH1A1LMNAKMT2AL3MBTL1
SCHEMBL5535923 0.84 LMNA (0.40) ALDH1A1LMNAKMT2AL3MBTL1
SCHEMBL5535927 0.84 LMNA (0.40) ALDH1A1LMNAKMT2AL3MBTL1
SCHEMBL6010636 0.83 ALDH1A1 (0.43) ALDH1A1MAPTLMNAVEGFAEGLN1
SCHEMBL6010609 0.83 ALDH1A1 (0.43) ALDH1A1MAPTLMNAVEGFAEGLN1
SCHEMBL5541421 0.83 ALDH1A1 (0.43) ALDH1A1MAPTLMNAVEGFAEGLN1
SCHEMBL5542523 0.81 ALDH1A1 (0.41) ALDH1A1MAPTLMNAVEGFAEGLN1
SCHEMBL5542233 0.80 MEN1 (0.41) ALDH1A1MAPTLMNAVEGFAEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ABCB1 2408/4885ALDH1A1 355/4885MAPT 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.